Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Frontiers in Oncology
|
April 28, 2025
Case Report: Abiraterone in brain metastases from prostate cancer
Tobias Peres, Stefanie Aeppli, Stefanie Fischer, et al.
Journal of Cancer Research and Clinical Oncology
|
February 8, 2024
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Tobias Peres, Stefanie Aeppli, Stefanie Fischer, et al.
Current Oncology (Toronto, Ont.)
|
February 25, 2025
First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland
Tobias Peres, Stefanie Aeppli, Stefanie Fischer, et al.
Targeted Oncology
|
June 10, 2025
A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines
Marie Wosny, Stefanie Aeppli, Stefanie Fischer, et al.
Cancer Medicine
|
October 22, 2024
Factors Guiding Clinical Decision-Making in Genitourinary Oncology
Marie Wosny, Stefanie Aeppli, Stefanie Fischer, et al.
Swiss Medical Weekly
|
June 26, 2022
Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018
Stefanie Aeppli, Daniel S Engeler, Stefanie Fischer, et al.
Studies in Health Technology and Informatics
|
August 8, 2025
Consensus Finding Among LLMs to Retrieve Information About Oncological Trials
Fabio Dennstädt, Paul Windisch, Irina Filchenko, et al.
Oncology
|
June 15, 2025
Application of a General Large Language Model-Based Classification System to Retrieve Information about Oncological Trials
Fabio Dennstädt, Paul Windisch, Irina Filchenko, et al.
ESMO Open
|
July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Stefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Melanoma Research
|
April 23, 2025
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)
Markus Joerger, Stefan Diem, Nina Wyss, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Frontiers in Oncology
|
April 28, 2025
Case Report: Abiraterone in brain metastases from prostate cancer
Tobias Peres, Stefanie Aeppli, Stefanie Fischer, et al.
Journal of Cancer Research and Clinical Oncology
|
February 8, 2024
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Tobias Peres, Stefanie Aeppli, Stefanie Fischer, et al.
Current Oncology (Toronto, Ont.)
|
February 25, 2025
First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland
Tobias Peres, Stefanie Aeppli, Stefanie Fischer, et al.
Targeted Oncology
|
June 10, 2025
A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines
Marie Wosny, Stefanie Aeppli, Stefanie Fischer, et al.
Cancer Medicine
|
October 22, 2024
Factors Guiding Clinical Decision-Making in Genitourinary Oncology
Marie Wosny, Stefanie Aeppli, Stefanie Fischer, et al.
Swiss Medical Weekly
|
June 26, 2022
Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018
Stefanie Aeppli, Daniel S Engeler, Stefanie Fischer, et al.
Studies in Health Technology and Informatics
|
August 8, 2025
Consensus Finding Among LLMs to Retrieve Information About Oncological Trials
Fabio Dennstädt, Paul Windisch, Irina Filchenko, et al.
Oncology
|
June 15, 2025
Application of a General Large Language Model-Based Classification System to Retrieve Information about Oncological Trials
Fabio Dennstädt, Paul Windisch, Irina Filchenko, et al.
ESMO Open
|
July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Stefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
Melanoma Research
|
April 23, 2025
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)
Markus Joerger, Stefan Diem, Nina Wyss, et al.
Page
of 2